Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Company Information
About this company
Key people
Cheryl Renee Blanchard
President, Chief Executive Officer, Director
Stephen D. Griffin
Chief Financial Officer, Chief Operating Officer, Executive Vice President
David B. Colleran
Executive Vice President, General Counsel, Secretary
Ian W. Mcleod
Chief Accounting Officer, Vice President, Treasurer
John Bell Henneman
Independent Chairman of the Board
Joseph H. Capper
Independent Director
Sheryl L. Conley
Independent Director
Gary P. Fischetti
Independent Director
William R. Jellison
Independent Director
Click to see more
Key facts
- Shares in issue15.36m
- EPICANIK
- ISINUS0352551081
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$141.90m
- Employees288
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.